Vimarsana
Biggest News Aggregation in the World

Page 4 - John Menditto News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Menditto. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Menditto Today - Breaking & Trending Today

Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time - Vimarsana News

Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., May 02, 2023 -- Lisata Therapeutics, Inc. , a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other... | May 2, 2023

Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma - Vimarsana News

Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

The iLSTA Trial is the first study combining LSTA1 with standard-of-care chemotherapy and immunotherapy WARPNINE to provide funding and local trial management BASKING RIDGE, N.J. and... | April 18, 2023

Lisata Therapeutics, Inc. (LSTA) Q3 2022 Earnings Call Transcript - Vimarsana News

Lisata Therapeutics, Inc. (LSTA) Q3 2022 Earnings Call Transcript

Lisata Therapeutics, Inc. (NASDAQ:NASDAQ:LSTA) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants John Menditto - VP, IR and Corporate Communications Dave...

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript - Vimarsana News

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript

Caladrius Biosciences, Inc. (NASDAQ:NASDAQ:CLBS) Q2 2022 Results Conference Call August 04, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David...

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology - Vimarsana News

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 -- Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse... | July 6, 2022